Identification of sacrococcygeal and pelvic abscesses infected with invasive Mycoplasma hominis by MALDI-TOF MS

Fang Su1 | Junwu Zhang2 © | Yongze Zhu1 | Huoyang Lv1 | Yumei Ge1,3 ©

Abstract
Background: Mycoplasma hominis is the smallest prokaryotic microorganism with no cell wall, high pleomorphism, and slower reproduction than bacteria. It is difficult for clinical technicians to find M. hominis through the negative Gram staining of specimens. Therefore, it is likely to miss detection in routine clinical smear etiological examination. M. hominis is generally considered to be a common colonizing bacterium in urogenital tract with low pathogenicity, and it is usually difficult to invade submucosal tissue and enter the bloodstream.

Methods: The abscesses of the patient were examined histopathologically, and the pus in the abscesses was extracted for etiological examination. MALDI-TOF MS was used to identify and confirmed the pathogens in the specimens. The commercial Mycoplasma isolation, culture, and drug sensitivity kit was used to determine antibiotic susceptibility.

Results: No pathogens were found after pathological and smear microscopic examination of the puncture fluid from the sacrococcygeal and pelvic abscesses. Until 48 h later, small, translucent, and gray-white colonies were observed in the blood plate culture results. The laboratory physician ultimately determined that the pathogen was M. hominis by MALDI-TOF MS.

Conclusion: We report a case of extra-urogenital cystic abscesses infected by M. hominis, in order to improve clinicians' comprehensive understanding of the pathogenicity of Mycoplasma. In addition, the clinical laboratory technician should pay attention to the role of Wright–Giemsa staining of puncture fluid smear in the preliminary detection and the application of MALDI-TOF MS in identification of uncommon pathogenic microorganisms.

KEYWORDS
matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS), Mycoplasma hominis (M. hominis MH), puncture fluid, sacrococcygeal and pelvic abscesses
1 | INTRODUCTION

*Mycoplasma hominis* (M. hominis) is a common colonization bacterium in the urogenital tract, it can be universally isolated from sexually mature women, approximately 21% to 53% of asymptomatic women are colonized with *M. hominis*, and the colonization rate of male urethra can be as high as 20%. Under certain conditions, *M. hominis* can cause urogenital tract infections such as pelvic inflammation and cervicitis, but its pathogenicity is weak. Generally, it only causes genital tract mucosal surface infection and does not invade tissues and blood. In this case, the special clinical manifestations of extra-urogenital cystic abscesses caused by *M. hominis* infection were identified by flight mass spectrometry rather than routine Gram staining and colony morphology.

2 | CASE PRESENTATION

2.1 | Patient and basic clinical information

A 70-year-old man with more than half a year’s history of an oval cystic abscess in sacrococcygeal region presented to the outpatient department with increasingly unbearable pain and fidgety inconvenience. High-resolution computed tomography (HRCT) of the sacrococcygeal vertebrae showed two connected oval cystic lesions involving in subcutaneous tissue and pelvic cavity (Figure 1). The surgeon performed resection of sacrococcygeal and pelvic abscesses at the request of the patient. The incision was about 7 cm long along the long axis of the cyst, the skin and subcutaneous tissue were cut in turn, the surrounding adhesive tissue was separated along the surface of the cyst, the cyst was completely stripped, the root was ligated with No. 4 silk thread, continued to separate downward, the pelvic abscess of about 40 × 30 mm was stripped, the subcutaneous fascia was free, sutured intermittently, and the incision was closed layer by layer.

2.2 | Routine smear etiological examination of histopathological and Gram staining

Both histopathological examination and Gram staining results of the specimens revealed numerous polymorphonuclear leukocytes with no visible pathogens (Figure 2). Pinpoint-sized translucent and gray-white colonies were observed on blood agar following 48 h of incubation under 5% CO<sub>2</sub> at 37 °C (Figure 3A). Microorganisms dyed lavender of different shapes were observed by Wright–Giemsa staining under a 100× oil microscope (Figure 3B). VITEK 2-compact automatic bacterial detection and analysis system (BioMérieux), one of the most commonly used identification methods of bacteria and Candida in clinic, was failed in this detection.

2.3 | MALDI-TOF MS identification and Wright–Giemsa staining results

MALDI-TOF MS was used to identify and confirmed that the pathogen was *M. hominis* with the confidence of 99.9% (database VITEK MS IVD 3.0 and SARAMIS V4.14) (Figure 3D). Wright–Giemsa staining results of the puncture fluid of the abscesses showed that the existence of the microorganisms of different shapes was confirmed again (Figure 3C).

2.4 | Antimicrobial susceptibility of the isolated strain

The commercial *Mycoplasma* (*Ureaplasma urealyticum / M. hominis*) isolation, culture, and drug sensitivity kit (Zhuhai DL) was used to determine antibiotic susceptibility by using the Clinical and Laboratory Standards Institute (CLSI) breakpoints. The isolate was susceptible to doxycycline, erythromycin, minocycline, and josamycin, while resistant to ciprofloxacin, clindamycin, tetracycline, levofloxacin,
ofloxacin, roxithromycin, sparfloxacin, and azithromycin (Table 1). After 3 days of anti-infection treatment, the patient’s condition improved significantly and was discharged after expert evaluation.

3 | DISCUSSION

Urogenital inflammation caused by *M. hominis* infection mainly includes urinary tract infection, cervicitis, pelvic inflammation, vaginitis, chorioamnionitis, and premature abortion and infertility related to *Mycoplasma* infection. These diseases have been widely reported and are often limited to the surface of urogenital mucosa. It is generally considered that *M. hominis* is a low virulence opportunistic pathogen. Therefore, invasive *M. hominis* infection outside the urogenital tract is possible to be ignored by clinicians. What is more worrying is that *M. hominis* is gram-negative due to its lack of cell wall and has no response to all antibiotics targeting cell wall synthesis. This special biological characteristic makes it can not only escape the routine etiological examination such as Gram staining, but also escape the clinician’s empirical anti-infection treatment. The growth rate of *Mycoplasma* on the blood agar medium routinely used for pathogen proliferation is slower than that of common bacteria, it usually takes 48 h or even longer, and the colony morphology is not typical. Undetected report or untimely pathogen identification may cause an aggravation of the inflammation and lead to poor outcomes of complications and prolonged hospital stays.

At present, the clinical diagnosis of invasive *M. hominis* infection outside the urogenital tract is facing great challenges. In this case, clinicians did not tend to consider it as *M. hominis* infection at first, and they chose the etiological screening of puncture fluid rather than targeted *Mycoplasma* identification. From the results of histopathological examination and Gram staining, we intuitively found that a large number of leukocytes such as lymphocytes and granulocytes were distributed in the visual field, but there was a lack of visible microorganisms. Therefore, when we encountered such a contradictory phenomenon, the increased number of leukocytes indicated that there was inflammation in this region with a fierce struggle to resist the invasion of bacteria, but there was a lack of visible microorganism, and the infection possibility of pathogenic bacteria with negative conventional staining such as *M. hominis* should be considered. In this case, the pathogen of the abscesses was identified as *M. hominis* by MALDI-TOF MS. MALDI-TOF MS technology is a new soft ionization organic mass spectrometry developed in recent years. By detecting the characteristic protein peaks of the pathogenic microorganisms, the colonies can be identified and classified directly in a few minutes. At present, the flight mass spectrometry database contains 14 main *Mycoplasmas* causing human diseases, such as *M. hominis* and *M. pneumoniae*. This method has
FIGURE 3  Positive etiological analysis images of colony morphology, Wright–Giemsa staining, and MALDI-TOF MS detection. Pinpoint-sized translucent and gray-white colonies, later identified as *M. hominis*, on blood agar following 48 h of incubation under 5% CO₂ at 37 °C (Figure A). The colonies on the blood agar plate were stained with Wright–Giemsa staining and small round or rod-shaped bacteria dyed lavender could be observed under a 100× oil microscope (Figure B). We re-stained the puncture fluid of the abscess, and Wright–Giemsa staining was used. The results showed that the pleomorphic leukocytes were surrounded by microorganisms of different shapes dyed lavender, with a diameter of about 1–3 mm (100× oil lens and 10× eyepiece) (Figure C). Matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) (BioMérieux) was used to identify and confirmed that the pathogen was *M. hominis* with the confidence of 99.9% (database VITEK MS IVD 3.0 and SARAMIS V4.14) (Figure D).

TABLE 1  Antibiotic sensitivity test results of the isolate from the puncture fluid of the abscesses of the patient

| Antibiotics     | Quantitative results (μg/ml) | Sensitivity | Methodology | Break point range of antibiotic sensitivity          |
|-----------------|------------------------------|-------------|-------------|-----------------------------------------------------|
| Ciprofloxacin   | ≥4                           | Resistant   | MIC         | 0.25–1                                              |
| Clindamycin     | ≥8                           | Resistant   | MIC         | Derived from the results                             |
| Doxycycline     | ≤4                           | Susceptible | MIC         | 4–6                                                 |
| Erythromycin    | ≤1                           | Susceptible | MIC         | Derived from the results                             |
| Tetracycline    | ≥16                          | Resistant   | MIC         | 4–6                                                 |
| Levofloxacin    | ≥8                           | Resistant   | MIC         | Derived from the results                             |
| Minocycline     | ≤4                           | Susceptible | MIC         | 4–6                                                 |
| Ofloxacin       | ≥8                           | Resistant   | MIC         | 2–8                                                 |
| Roxithromycin   | ≥8                           | Resistant   | MIC         | Derived from the results                             |
| Sparfloxacin    | ≥8                           | Resistant   | MIC         | 0.5–2                                               |
| Azithromycin    | ≥8                           | Resistant   | MIC         | 2–8                                                 |
| Josamycin       | ≤2                           | Susceptible | MIC         | Derived from the results                             |
the advantages of simple and fast operation, relatively low cost, accurate identification results, and high repeatability, and significantly reduces the cost of consumables and the time of identification and diagnosis. When the traditional colony morphology identification and VITEK 2-compact automatic bacterial detection and analysis system cannot be determined in clinical laboratory, MALDI-TOF MS is a favored alternative method.

Extra-urogenital tract infection caused by invasive *M. hominis* should be paid attention to. In recent years, for patients with low immune function or defects, *M. hominis* can penetrate the mucosa, invade the vascular walls, and spread to all tissues and organs of the body. 17-19 Surgical incision infection, postoperative blood flow infection, post cardiopulmonary transplantation infection, and other cases have been reported from time to time. 20-22 In addition, infants whose immune function is not yet fully developed often have serious clinical manifestations by infecting *M. hominis* in utero or through vertical transmission. 23 The latest research found that *M. hominis* is the main respiratory pathogens in severe novel coronavirus pneumonia in the investigation of SARS-CoV-2-related microbial dysbiosis and various antibiotic-resistant respiratory pathogens in hospitalized COVID-19 patients, including 8 mildly and 15 severely ill patients in Guangdong province, China. 24

4 CONCLUSION

Although *M. hominis* as a colonization of urogenital tract is common in the human body, attention should be paid to the possibility of invasive *M. hominis* infection when patients have chronic diseases such as trauma, diabetes and infectious diseases such as HIV infection, and other immunodeficiency or deficiency conditions, such as tumor and chemotherapy, organ transplant, and immunosuppressive usage. Because the selection of antibiotics for the treatment of *M. hominis* infection is highly targeted, timely and accurate etiological results are of great positive significance to prevent antibiotic resistance, shorten the course of disease, and reduce the cost of treatment.

ACKNOWLEDGMENTS

We thank all members of the microbiology laboratory of Zhejiang Provincial People’s Hospital for their help in the collection of clinical data and thank the patient for his cooperation.

CONFLICT OF INTEREST

The authors declare that they have no competing interests.

AUTHORS’ CONTRIBUTIONS

FS collects the patient clinical information. JWZ, YZZ, and HYL analyzed the data. YMG drawn the manuscript. All authors read and approved the final manuscript.

CONSENT FOR PUBLICATION

Written and informed consent was obtained from the patient for publication of this Case Report and any accompanying images.

REFERENCES

1. Waites KB, Xiao L, Paralanov V, et al. Molecular methods for the detection of *Mycoplasma* and *ureaplasma* infections in humans: a paper from the 2011 William Beaumont Hospital Symposium on molecular pathology. J Mol Diagn. 2012;14(5):437-450.

2. Horner P, Donders G, Cusini M, et al. Should we be testing for urogenital *Mycoplasma hominis*, *Ureaplasma parvum* and *Ureaplasma urealyticum* in men and women? A position statement from the European STI Guidelines Editorial Board. J Eur Acad Dermatol Venereol. 2018;32(11):1845-1851.

3. Shao L, Wu X, Gao S, et al. Epidemiological investigation and antimicrobial susceptibility analysis of *Ureaplasma* and *Mycoplasma hominis* in a teaching hospital in Shenyang, China. J Infect Chemother. 2021;27(8):1212-1216.

4. Stabler S, Faure E, Duployez C, et al. The brief case: *Mycoplasma hominis* Exteragenital abscess. J Clin Microbiol. 2021;59(4):e02343-e2420.

5. Clinical and Laboratory Standards Institute. Methods for Antimicrobial Susceptibility Testing for Human *Mycoplasmas; Approved Guideline; CLSI document M43-A1. Clinical and Laboratory Standards Institute: 2011.

6. Agger WA, Siddiqui D, Lovrich SD, et al. Epidemiologic factors and urogenital infections associated with preterm birth in a midwestern U.S. population. Obstet Gynecol. 2014;124(5):969-977.

7. Vouga M, Greub G, Prod’hom G, et al. Treatment of genital mycoplasma in colonized pregnant women in late pregnancy is associated with a lower rate of premature labour and neonatal complications. Clin Microbiol Infect. 2014;20(10):1074-1079.

8. Paia DA, Molina G, Tissera AD, et al. Results from a large cross-sectional study assessing Chlamydia trachomatis, *Ureaplasma* spp. and *Mycoplasma hominis* urogenital infections in patients with primary infertility. Sci Rep. 2021;11(1):13655.

9. Plummer EL, Vodstrcil LA, Bodiyabadu K, et al. Are *Mycoplasma hominis*, *Ureaplasma urealyticum* and *Ureaplasma parvum* associated with specific genital symptoms and clinical signs in nonpregnant women? Clin Infect Dis. 2021;73(4):659-668.

10. Chen X, Wang Y, Zhu J, et al. A sensitive and rapid assay for *Mycoplasma hominis* detection based on recombinase polymerase amplification. Clin Lab. 2021;67(4):1-2.

11. Saadat S, Karami P, Jafari M, et al. The silent presence of *Mycoplasma hominis* in patients with prostate cancer. Pathog Dis. 2020;78(7):37.

12. Wang H, Ren D, Li H, et al. Periprosthetic joint infection caused by *Mycoplasma hominis*, diagnosed using metagenomic sequencing. Int J Gen Med. 2021;14(1):7003-7006.

13. Cardot Martin E, Dolidon S, Lesprit P, et al. A strain uncoordinated women? EBioMedicine. 2017;19(1):8-9.

14. Gallo R, Tamborini AL, Di Bella H, et al. Actinotignum schaillii: reporte de dos casos de bacteriemias en Argentina [Actinotignum schaillii: Report of two cases of bacteremia in Argentina]. Rev Argent Microbiol. 2021;53(25):7541(21):97-103.

15. Sekercioglu AO, Cekin Y, Ogunc D, et al. Matrix-assisted laser desorption-ionization time-of-flight mass spectrometry (MALDI-TOF MS) for early identification of septic patients. Clin Lab. 2017;63(4):839-844.

16. Smibert OC, Wilson HL, Asma S, et al. Donor-derived *Mycoplasma hominis* and an apparent cluster of *M. hominis* cases in solid organ transplant recipients. Clin Infect Dis. 2017;65(9):1504-1508.

ORCID

Junwu Zhang https://orcid.org/0000-0002-8536-2080

Yumei Ge https://orcid.org/0000-0003-3321-2176
18. Sampath R, Patel R, Cunningham SA, et al. Cardiothoracic transplant recipient Mycoplasma hominis: an uncommon infection with probable donor transmission. *EBioMedicine*. 2017;19(1):84-90.

19. Meyer RD, Clough W. Exogenous *Mycoplasma hominis* infections in adults: emphasis on immunosuppression. *Clin Infect Dis*. 1993;17(1):S243-249.

20. Chen Y, Huang Z, Fang X, et al. Diagnosis and treatment of *Mycoplasma* septic arthritis: a systematic review. *Int Orthop*. 2020;44(2):199-213.

21. Hinić V, Seth-Smith HMB, Damm S, et al. Unexpected *Mycoplasma hominis* infection in two renal transplant recipients traced back to the same donor by whole-genome sequencing. *Eur J Clin Microbiol Infect Dis*. 2021;40(5):1097-1102.

22. Vecchio M, Koutsokera A, Touilloux B, et al. Bronchial anastomosis dehiscence and stenosis caused by donor-transmitted *Mycoplasma hominis* infection in a lung transplant recipient: Case report and literature review. *Transpl Infect Dis*. 2021;23(2):e13475.

23. Wildenbeest JG, Said I, Jaeger B, et al. Neonate with *Mycoplasma hominis* meningoencephalitis given moxifloxacin. *Lancet Infect Dis*. 2016;16(11):e261-e266.

24. Zhong H, Wang Y, Shi Z, et al. Characterization of respiratory microbial dysbiosis in hospitalized COVID-19 patients. *Cell Discov*. 2021;7(1):23.

**How to cite this article:** Su F, Zhang J, Zhu Y, Lv H, Ge Y. Identification of sacrococcygeal and pelvic abscesses infected with invasive *Mycoplasma hominis* by MALDI-TOF MS. *J Clin Lab Anal*. 2022;36:e24329. doi:10.1002/jcla.24329